Safety of TNKase Administration Outside the Approved Time Window

For Acute Myocardial Infarction (STEMI)

The American College of Cardiology recommends that TNKase should not be administered outside its approved time window except in specific circumstances where the benefits may outweigh the risks, such as in symptomatic STEMI patients presenting >12 hours after symptom onset with large areas of myocardium at risk or hemodynamic instability when PCI is unavailable 1, 2, 3
The benefits of fibrinolytic therapy, including TNKase, are well-established within 12 hours of symptom onset for STEMI patients, with greater benefit observed in those who present early after symptom onset 1
In symptomatic STEMI patients presenting >12 hours after symptom onset, TNKase may be considered if there is a large area of myocardium at risk, the patient has hemodynamic instability, or primary PCI is unavailable 2, 3
Absolute contraindications to TNKase must be strictly observed regardless of timing, including any prior intracranial hemorrhage, known structural cerebral vascular lesions, known malignant intracranial neoplasms, ischemic stroke within 3 months, active bleeding or bleeding diathesis, and suspected aortic dissection 1, 4

Primary PCI remains the preferred reperfusion strategy for STEMI, especially beyond the 12-hour window 1, 2
If PCI is not available and the patient presents >12 hours after symptom onset, assess for ongoing symptoms suggesting continuing ischemia, evaluate the extent of myocardium at risk, consider the patient's hemodynamic stability, and carefully review all contraindications 1, 2, 3, 4

Administering TNKase outside approved windows without careful patient selection increases bleeding risk, particularly intracranial hemorrhage 1
Failing to transfer patients to PCI-capable centers after fibrinolytic therapy, even when administered in extended windows 1, 2
Overlooking absolute contraindications when considering extended window treatment 1, 4
Not considering the higher bleeding risk in elderly patients when administering thrombolytics outside standard windows 2, 4

The American College of Cardiology and the American Heart Association recommend that tenecteplase should not be routinely administered to patients with STEMI presenting more than 12 hours after symptom onset, unless there is clinical evidence of ongoing ischemia, a large area of myocardium at risk, or hemodynamic instability, and primary PCI is not available 5, 6

The benefit of fibrinolytic therapy in patients who present >12 hours after symptom onset has not been well established in clinical trials, with a Class IIa recommendation (Level of Evidence: C) for fibrinolytic therapy in patients presenting 12-24 hours after symptom onset 5, 7

The American College of Cardiology recommends primary PCI over fibrinolytic therapy when available for patients presenting >12 hours after symptom onset, as it can reduce infarct size and improve left ventricular ejection fraction 6, 8
Transfer to a PCI-capable hospital is reasonable for patients presenting 12-24 hours after symptom onset to reduce infarct size and MACE 6, 8

The American Heart Association recommends carefully assessing for absolute contraindications to fibrinolytic therapy, including severe uncontrolled hypertension 6
Evaluate for evidence of ongoing ischemia, such as persistent chest pain or <50% resolution of ST-segment elevation 6
Assess the extent of myocardium at risk, including location of infarct and number of leads with ST elevation 5
Consider hemodynamic status, including presence of heart failure, cardiogenic shock, or hemodynamic instability 5, 6, 8

Administer tenecteplase as a single weight-adjusted IV bolus, with adjunctive therapy including aspirin, clopidogrel, and anticoagulation with unfractionated heparin or enoxaparin 5, 7
Transfer to a PCI-capable facility after fibrinolytic therapy for routine coronary angiography 6